title: Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways.
abstract: Ischemic preconditioning is characterized by resistance to ischemia reperfusion injury in response to previous short ischemic episodes, a protective effect that can be mimicked pharmacologically. The underlying mechanism of protection remains controversial and requires greater understanding before it can be fully exploited therapeutically. To investigate the overall effect of preconditioning on the myocardial proteome, isolated rabbit ventricular myocytes were treated with drugs known to induce preconditioning, adenosine or diazoxide (each at 100 micromol/L for 60 minutes). Their protein profiles were then compared with vehicle-treated controls (n=4 animals per treatment) using a multitiered 2D gel electrophoresis approach. Of 28 significantly altered protein spots, 19 nonredundant proteins were identified (5 spots remained unidentified). The majority of these proteins are involved in mitochondrial energetics, including subunits of tricarboxylic acid cycle enzymes and oxidative phosphorylation complexes. These changes were not indiscriminate, with only a small number of enzymes or complex subunits altered, indicating a very specific and targeted affect of these 2 preconditioning mimetics. Among the changes were shifts in the extent of posttranslational modification of 4 proteins. One of these, the adenosine-induced phosphorylation of the ATP synthase beta subunit, was fully characterized with the identification of 5 novel phosphorylation sites. This proteomics approach provides an overall assessment of the cellular response to pharmacological treatment with adenosine and diazoxide and identifies a distinct subset of enzymes and protein complex subunit that may underlie the preconditioned phenotype.
authors.affiliation: Department of Physiology, Queen's University, Kingston, Ontario, Canada.
authors.forename: D Kent
authors.initials: DK
authors.lastname: Arrell
authors.forename: Steven T
authors.initials: ST
authors.lastname: Elliott
authors.forename: Lesley A
authors.initials: LA
authors.lastname: Kane
authors.forename: Yurong
authors.initials: Y
authors.lastname: Guo
authors.forename: Young H
authors.initials: YH
authors.lastname: Ko
authors.forename: Pete L
authors.initials: PL
authors.lastname: Pedersen
authors.forename: John
authors.initials: J
authors.lastname: Robinson
authors.forename: Mitsushige
authors.initials: M
authors.lastname: Murata
authors.forename: Anne M
authors.initials: AM
authors.lastname: Murphy
authors.forename: Eduardo
authors.initials: E
authors.lastname: Marbán
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Van Eyk
mesh_terms: D000241:Adenosine / Q000494:pharmacology*; D000818:Animals; D003981:Diazoxide / Q000494:pharmacology*; D006352:Heart Ventricles; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D009206:Myocardium / Q000378:metabolism*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics; D011817:Rabbits
chemical_list: D020543:Proteome; D000241:Adenosine; D003981:Diazoxide